Chargement en cours...
EXTH-05. miR-34a INHIBITS GLIOBLASTOMA CELL PROLIFERATION AND SENSITIZES TO TEMOZOLOMIDE
Glioblastoma (GBM) is the most common primary brain tumor with a median survival of 14.5 months, despite maximal therapy consisting of surgical resection, radiation and temozolomide (TMZ). Genetic profiling has shown an average of three driver mutations localized to the p53, Rb and receptor tyrosine...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5691989/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.301 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|